123 related articles for article (PubMed ID: 38221859)
1. Prusogliptin (DBPR108) monotherapy in treatment-naïve patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study.
Wang W; Guo X; Zhang C; Ning T; Ma G; Huang Y; Jia R; Zhou D; Cao M; Zhang T; Yao L; Yuan J; Chen L;
Diabetes Obes Metab; 2024 Apr; 26(4):1321-1332. PubMed ID: 38221859
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.
Xu J; Ling H; Geng J; ; Huang Y; Xie Y; Zheng H; Niu H; Zhang T; Yuan J; Xiao X
Diabetes Obes Metab; 2022 Nov; 24(11):2232-2240. PubMed ID: 35791646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Gantz I; Okamoto T; Ito Y; Okuyama K; O'Neill EA; Kaufman KD; Engel SS; Lai E;
Diabetes Obes Metab; 2017 Nov; 19(11):1602-1609. PubMed ID: 28449368
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial.
Wang W; Yao J; Guo X; Guo Y; Yan C; Liu K; Zhang Y; Wang X; Li H; Wen Z; Wang X; Li S; Xiao X; Liu W; Li Z; Zhang L; Shao S; Ye S; Qin G; Li Y; Li F; Zhang X; Li X; Peng Y; Deng H; Xu X; Zhou L; Huang Y; Cao M; Xia X; Shi M; Dou J; Yuan J
Curr Med Res Opin; 2020 Jul; 36(7):1107-1115. PubMed ID: 32338063
[No Abstract] [Full Text] [Related]
7. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
8. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Seino Y; Kaku K; Kadowaki T; Okamoto T; Sato A; Shirakawa M; O'Neill EA; Engel SS; Kaufman KD
Diabetes Obes Metab; 2021 Jun; 23(6):1342-1350. PubMed ID: 33565686
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
16. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
[TBL] [Abstract][Full Text] [Related]
19. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
20. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
